Advertisement
Screener

AYTU BIOPHARMA, INC (AYTU) Proceeds from Contributed Capital

2.8 / 5 stars · 68/120 Roast Me

AYTU BIOPHARMA, INC Proceeds from Contributed Capital

AYTU BIOPHARMA, INC (AYTU) reported Proceeds from Contributed Capital of $0 for the 6-month period ending 2015-12-31, per its 10-Q filed 2016-02-11.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromContributedCapital · last filed 2016-02-11

  • AYTU BIOPHARMA, INC proceeds from contributed capital for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
  • AYTU BIOPHARMA, INC proceeds from contributed capital for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
  • AYTU BIOPHARMA, INC proceeds from contributed capital for the quarter ending 2014-12-31 was $500.00K.
  • AYTU BIOPHARMA, INC proceeds from contributed capital for the quarter ending 2014-09-30 was $600.00K.
  • AYTU BIOPHARMA, INC proceeds from contributed capital for fiscal 2014 was $637.21K.
  • AYTU BIOPHARMA, INC proceeds from contributed capital for fiscal 2009 was $1.76K, a 162.63% increase from fiscal 2008.
  • AYTU BIOPHARMA, INC proceeds from contributed capital for fiscal 2008 was $669.00, a 27.68% decline from fiscal 2007.
  • AYTU BIOPHARMA, INC proceeds from contributed capital for fiscal 2007 was $925.00, a 52.93% decline from fiscal 2006.
Period endProceeds from Contributed Capital 3 monthProceeds from Contributed Capital 6 monthProceeds from Contributed Capital 9 monthProceeds from Contributed Capital 12 monthProceeds from Contributed Capital 108 monthProceeds from Contributed Capital 111 month
2015-12-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-11
$0.00
10-Q · filed 2016-02-11
2015-09-30$0.00
10-Q · filed 2015-11-06
2014-12-31$500.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-11
$1.10M
10-Q · filed 2016-02-11
$1.10M
derived: sum of 3 quarters · filed 2016-02-11
2014-09-30$600.00K
10-Q · filed 2015-11-06
$600.00K
derived: sum of 2 quarters · filed 2015-11-06
2014-06-30$1.00
derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-28
$637.21K
10-K · filed 2015-09-28
2014-05-31$900.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-07-10
$2.64K
10-Q · filed 2014-07-10
$43.36K
10-Q · filed 2014-07-10
2014-03-31$637.21K
10-Q · filed 2015-05-19
2014-02-28$1.74K
10-Q · filed 2014-04-11
$42.46K
10-Q · filed 2014-04-11
2013-05-31$2.09K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-07-10
$5.49K
10-Q · filed 2014-07-10
2013-02-28$3.40K
10-Q · filed 2014-04-11
2009-08-31$1.76K
10-K · filed 2014-11-26
2008-08-31$669.00
10-K · filed 2014-11-26
2007-08-31$925.00
10-K · filed 2014-11-26
2006-08-31$1.97K
10-K · filed 2014-11-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
NextCure, Inc. (NXTC)United States$0.024B-0.15
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
ARTELO BIOSCIENCES, INC. (ARTL)United States$0.023B
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77